RESUMEN
BACKGROUND: Biomarkers are important for guiding the clinical and therapeutic management of all phases of rheumatoid arthritis because they can help to predict disease development in subjects at risk, improve diagnosis by closing the serological gap, provide prognostic information that is useful for making therapeutic choices and assessing treatment responses and outcomes, and allow disease activity and progression to be monitored. Various biomarkers can be used to identify subjects susceptible to the disease and those with pre-clinical rheumatoid arthritis before the onset of symptoms such as rheumatoid factor and anti-citrullinated protein antibodies. They can be correlated with a risk of developing rheumatoid arthritis and can predict more bone erosions and severe disease progression. Biomarkers such as the erythrocyte sedimentation rate and C-reactive protein levels provide information about disease activity, while predictive biomarkers allow clinicians to assess the probability of a treatment response before starting a particular therapy particularly in the era of biological drugs. This move from traditional approaches to patient stratification and targeted treatment should greatly improve patient care and reduce medical costs.
Asunto(s)
Artritis Reumatoide/sangre , Anticuerpos Antiproteína Citrulinada/sangre , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/terapia , Biomarcadores/sangre , Sedimentación Sanguínea , Proteína C-Reactiva/análisis , Humanos , Pronóstico , Factor Reumatoide/sangre , Resultado del TratamientoRESUMEN
Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.
Asunto(s)
Antirreumáticos , Artritis Psoriásica/terapia , Enfermedades Pulmonares Intersticiales/etiología , Fibrosis Pulmonar/etiología , Espondilitis Anquilosante/terapia , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/inmunología , Antirreumáticos/efectos adversos , Antirreumáticos/inmunología , Artritis Psoriásica/inmunología , Humanos , Enfermedades Pulmonares Intersticiales/diagnóstico , Pronóstico , Fibrosis Pulmonar/diagnóstico , Espondilitis Anquilosante/inmunologíaRESUMEN
Long-term extension studies and observational drug registers have revealed an increased risk of serious infections in patients treated with anti-tumor necrosis factor agents, particularly infliximab, etanercept and adalimumab. The same may be true for the newer biological drugs rituximab, tocilizumab and abatacept, although this has yet to be confirmed by long-term observational studies. We review the risk of tuberculosis, herpes zoster and other opportunistic infections, and the recommendations for screening for tuberculosis and hepatitis B and C infections in patients with rheumatoid arthritis, with the aim of informing patients and encouraging greater awareness among physicians.
Asunto(s)
Terapia Biológica , Certolizumab Pegol/efectos adversos , Infliximab/efectos adversos , Interleucina-6/antagonistas & inhibidores , Enfermedades Reumáticas/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Terapia Biológica/efectos adversos , Terapia Biológica/métodos , Certolizumab Pegol/administración & dosificación , Quimioterapia Combinada/efectos adversos , Humanos , Infecciones/epidemiología , Infecciones/etiología , Infliximab/administración & dosificación , Enfermedades Reumáticas/metabolismo , Índice de Severidad de la EnfermedadRESUMEN
INTRODUCTION: Patients with rheumatoid arthritis (RA) or other rheumatic diseases say that pain and stiffness are symptoms affecting their quality of life. Ketoprofen and ibuprofen are the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and manage mild-to-moderate pain. The aim of this new systematic review of the literature and meta-analysis of randomized controlled trials (RCTs) was to compare the clinical efficacy of ketoprofen and ibuprofen in patients with RA. METHODS: The MEDLINE and EMBASE scientific databases were systematically searched from their inception to November 2020 to identify RCTs directly comparing the recommended therapeutic doses of oral ketoprofen (50-200 mg/day) with ibuprofen (600-1800 mg/day) for RA pain relief. The meta-analysis was made using the standardized mean differences (SMD) of each of the identified RCTs using a fixed effects model. RESULTS: Four RCTs involving 456 patients met the inclusion criteria. The results of the meta-analysis showed a statistically significant difference in efficacy in favor of ketoprofen (0.33, 95% CI 0.14-0.52, p = 0.0005) at all point-estimates of the mean-weighted size effect. The heterogeneity test for the efficacy outcome (the hypothesis was χ2 = 3.57%, df = 3, p value = 0.31 and the chance of a test effect was 3.49, p = 0.0005) was not significant, and this was confirmed by a Higgins percentage of 16%. The studies included in the meta-analysis did not reveal any significant differences between the two drugs in terms of tolerability or safety. CONCLUSIONS: The result of this meta-analysis shows that ketoprofen is more effective than ibuprofen in managing RA pain at therapeutic doses, thus supporting its use in clinical practice.